中华皮肤科杂志 ›› 2025, Vol. 58 ›› Issue (11): 1003-1008.doi: 10.35541/cjd.20250262
孙青
收稿日期:2025-05-12
修回日期:2025-06-26
发布日期:2025-11-03
通讯作者:
孙青
E-mail:sunqing7226@163.com
Sun Qing
Received:2025-05-12
Revised:2025-06-26
Published:2025-11-03
Contact:
Sun Qing
E-mail:sunqing7226@163.com
摘要： 【摘要】 银屑病是一种免疫介导的慢性、复发性、炎症性、系统性疾病。随着对其发病机制认识的不断深入，银屑病治疗策略已从传统的抗炎和免疫抑制转变为针对特定的细胞因子/炎症通路的精准靶向干预，显著提升了治疗的有效性和安全性。本文介绍银屑病的治疗现状，并基于临床研究证据阐述银屑病治疗进展及新趋势。
孙青. 银屑病治疗现状与进展[J]. 中华皮肤科杂志, 2025,58(11):1003-1008. doi:10.35541/cjd.20250262
Sun Qing. Therapeutic strategies for psoriasis: current status and progress[J]. Chinese Journal of Dermatology, 2025, 58(11): 1003-1008.doi:10.35541/cjd.20250262
| ［1］ | Parisi R, Iskandar I, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study［J］. BMJ, 2020,369:m1590. doi: 10.1136/bmj.m1590. |
| ［2］ | 中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2023版）［J］. 中华皮肤科杂志, 2023,56（7）:573⁃625. doi: 10.35541/cjd.20220839. |
| ［3］ | Yélamos O, Puig L. Systemic methotrexate for the treatment of psoriasis［J］. Expert Rev Clin Immunol, 2015,11（5）:553⁃563. doi: 10.1586/1744666X.2015.1026894. |
| ［4］ | Paul C, Gallini A, Maza A, et al. Evidence⁃based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists［J］. J Eur Acad Dermatol Venereol, 2011,25 Suppl 2:2⁃11. doi: 10.1111/j.1468⁃3083.2011.03990.x. |
| ［5］ | Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study［J］. Ann Rheum Dis, 2018,77（2）:228⁃233. doi: 10.1136/annrheumdis⁃ 2017⁃212196. |
| ［6］ | Hillary T, Lovegrove F, Boye T, et al. Certolizumab pegol for plaque psoriasis in women of childbearing potential, pregnant or breastfeeding in clinical settings: one⁃year outcomes from the international noninterventional CIMREAL study［J］. J Eur Acad Dermatol Venereol, 2025,39（6）:e532⁃e536. doi: 10.1111/jdv. 20516. |
| ［7］ | Phan DB, Elyoussfi S, Stevenson M, et al. Biosimilars for the treatment of psoriasis: a systematic review of clinical trials and observational studies［J］. JAMA Dermatol, 2023,159（7）:763⁃771. doi: 10.1001/jamadermatol.2023.1338. |
| ［8］ | Phan DB, Yiu ZZ. Biosimilars for the treatment of psoriasis: a narrative review［J］. Ital J Dermatol Venerol, 2024,159（6）:663⁃675. doi: 10.23736/S2784⁃8671.24.08083⁃6. |
| ［9］ | Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate⁃to⁃severe psoriasis （ECLIPSE）: results from a phase 3, randomised controlled trial［J］. Lancet, 2019,394（10201）:831⁃839. doi: 10.1016/S0140⁃6736（19）31773⁃8. |
| ［10］ | Gisondi P, Bellinato F, Galeone C, et al. Risk of developing psoriatic arthritis in patients with psoriasis initiating treatment with different classes of biologics［J］. Ann Rheum Dis, 2025,84（3）:435⁃441. doi: 10.1016/j.ard.2025.01.006. |
| ［11］ | Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis （BE READY）: a multicentre, double⁃blind, placebo⁃controlled, randomised withdrawal phase 3 trial［J］. Lancet, 2021,397（10273）:475⁃486. doi: 10.1016/S0140⁃6736（21）00126⁃4. |
| ［12］ | Merola JF, Landewé R, McInnes IB, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor⁃α inhibitors: a randomised, double⁃blind, placebo⁃controlled, phase 3 trial （BE COMPLETE）［J］. Lancet, 2023,401（10370）:38⁃48. doi: 10. 1016/S0140⁃6736（22）02303⁃0. |
| ［13］ | Morita A, Strober B, Burden AD, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares （Effisayil 2）: an international, multicentre, randomised, placebo⁃controlled trial［J］. Lancet, 2023,402（10412）:1541⁃1551. doi: 10.1016/S0140⁃6736（23）01378⁃8. |
| ［14］ | Strober B, Thaçi D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52⁃week, randomized, double⁃blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial［J］. J Am Acad Dermatol, 2023,88（1）:40⁃51. doi: 10.1016/j.jaad.2022.08.061. |
| ［15］ | McInnes IB, Anderson JK, Magrey M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis［J］. N Engl J Med, 2021,384（13）:1227⁃1239. doi: 10.1056/NEJMoa2022516. |
| ［16］ | Keam SJ. Tapinarof cream 1%: first approval［J］. Drugs, 2022,82（11）:1221⁃1228. doi: 10.1007/s40265⁃022⁃01748⁃6. |
| ［17］ | Papp KA, Weinberg MA, Morris A, et al. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo⁃controlled, phase 2b study［J］. Lancet, 2021,397（10284）:1564⁃1575. doi: 10.1016/S0140⁃6736（21）00440⁃2. |
| ［18］ | Reich K, Cullen E, Weinberg M. Maintenance of response in moderate⁃to⁃severe psoriasis after withdrawal of the interleukin （IL）⁃17A and IL⁃17F nanobody sonelokimab: is there a role for IL⁃17F in disease reoccurrence?［J］. Br J Dermatol, 2022,187（4）:591⁃593. doi: 10.1111/bjd.21617. |
| ［19］ | Kim D, Yang S, Gill M, et al. Next⁃generation anti⁃IL⁃17 agents for psoriatic disease: a pipeline review［J］. Am J Clin Dermatol, 2025,26（3）:307⁃320. doi: 10.1007/s40257⁃025⁃00928⁃w. |
| ［20］ | Gerdes S, Staubach P, Dirschka T, et al. Izokibep for the treatment of moderate⁃to⁃severe plaque psoriasis: a phase Ⅱ, randomized, placebo⁃controlled, double⁃blind, dose⁃finding multicentre study including long⁃term treatment［J］. Br J Dermatol, 2023,189（4）:381⁃391. doi: 10.1093/bjd/ljad186. |
| ［21］ | Warren RB, Reich A, Kaszuba A, et al. Imsidolimab, an anti⁃interleukin⁃36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phaseⅡ GALLOP trial［J］. Br J Dermatol, 2023,189（2）:161⁃169. doi: 10.1093/bjd/ljad083. |
| ［22］ | A phase 3 multicenter, randomized, double⁃blind, placebo⁃controlled study to evaluate the efficacy and safety of JNJ⁃77242113 for the treatment of participants with moderate to severe plaque psoriasis with randomized withdrawal and retreatment［DB/OL］. （2025⁃04⁃25）［2025⁃05⁃05］. https://clinicaltrials.gov/study/NCT06095115. |
| ［23］ | Warren RB, French LE, Blauvelt A, et al. Orismilast in moderate⁃to⁃severe psoriasis: efficacy and safety from a 16⁃week, randomized, double⁃blinded, placebo⁃controlled, dose⁃finding, and phase 2b trial （IASOS）［J］. J Am Acad Dermatol, 2024,90（3）:494⁃503. doi: 10.1016/j.jaad.2023.11.005. |
| ［24］ | Warren RB, Strober B, Silverberg JI, et al. Oral orismilast: efficacy and safety in moderate⁃to⁃severe psoriasis and development of modified release tablets［J］. J Eur Acad Dermatol Venereol, 2023,37（4）:711⁃720. doi: 10.1111/jdv.18812. |
| ［25］ | Gyldenløve M, Meteran H, Sørensen JA, et al. Efficacy and safety of oral roflumilast for moderate⁃to⁃severe psoriasis⁃a randomized controlled trial （PSORRO）［J］. Lancet Reg Health Eur, 2023,30:100639. doi: 10.1016/j.lanepe.2023.100639. |
| ［26］ | Gyldenløve M, Sørensen JA, Fage S, et al. Effects of oral roflumilast therapy on body weight and cardiometabolic parameters in patients with psoriasis ⁃ results from a randomized controlled trial （PSORRO）［J］. J Am Acad Dermatol, 2024,91（1）:64⁃71. doi: 10.1016/j.jaad.2024.02.036. |
| ［27］ | Armstrong AW, Gooderham M, Lynde C, et al. Tyrosine kinase 2 inhibition with zasocitinib （TAK⁃279） in psoriasis: a randomized clinical trial［J］. JAMA Dermatol, 2024,160（10）:1066⁃1074. doi: 10.1001/jamadermatol.2024.2701. |
| ［28］ | Forman SB, Pariser DM, Poulin Y, et al. TYK2/JAK1 inhibitor PF⁃06700841 in patients with plaque psoriasis: phase iia, randomized, double⁃blind, placebo⁃controlled trial［J］. J Invest Dermatol, 2020,140（12）:2359⁃2370.doi: 10.1016/j.jid. 2020. 03.962. |
| ［29］ | Mease P, Helliwell P, Silwinska⁃Stanczyk P, et al. Efficacy and safety of the TYK2/JAK1 inhibitor brepocitinib for active psoriatic arthritis: a phase ⅡB randomized controlled trial［J］. Arthritis Rheumatol, 2023,75（8）:1370⁃1380. doi: 10.1002/art. 42519. |
| ［30］ | Papp KA, Beyska⁃Rizova S, Gantcheva ML, et al. Efficacy and safety of piclidenoson in plaque psoriasis: results from a randomized phase 3 clinical trial （COMFORT⁃1）［J］. J Eur Acad Dermatol Venereol, 2024,38（6）:1112⁃1120. doi: 10.1111/jdv.19811. |
| ［31］ | A phase 2, international, multicenter, randomized, double⁃blind, placebo⁃controlled, dose⁃ranging study of efficacy and safety of SAR441566 in adults with moderate to severe plaque psoriasis ［DB/OL］. （2025⁃01⁃23）［2025⁃05⁃05］. https://clinicaltrials.gov/study/NCT06073119. |
| ［32］ | A Phase 2, multicenter, randomized, double⁃blind, placebo⁃controlled, parallel⁃group, dose ranging study of LY4100511 （DC⁃853） for the treatment of adult participants with moderate⁃to severe plaque psoriasis［DB/OL］. （2025⁃04⁃17）［2025⁃05⁃05］. https://clinicaltrials.gov/study/NCT06602219. |
| ［33］ | A randomized, double⁃blind, placebo⁃controlled study to assess the efficacy and safety of SCD⁃044 in the treatment of moderate to severe plaque psoriasis［DB/OL］. （2025⁃04⁃23）［2025⁃05⁃05］. https://clinicaltrials.gov/study/NCT04566666. |
| ［34］ | Hashim PW, Chima M, Kim HJ, et al. Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: a double⁃blind, randomized, vehicle⁃controlled trial［J］. J Am Acad Dermatol, 2020,82（2）:360⁃365. doi: 10.1016/j.jaad.2019.06.1288. |
| ［35］ | Lebwohl MG, Kircik LH, Moore AY, et al. Effect of roflumilast cream vs vehicle cream on chronic plaque psoriasis: the DERMIS⁃1 and DERMIS⁃2 randomized clinical trials［J］. JAMA, 2022,328（11）:1073⁃1084. doi: 10.1001/jama.2022.15632. |
| ［36］ | Lebwohl MG, Papp KA, Stein Gold L, et al. Trial of roflumilast cream for chronic plaque psoriasis［J］. N Engl J Med, 2020,383（3）:229⁃239. doi: 10.1056/NEJMoa2000073. |
| ［37］ | Kircik LH, Alonso⁃Llamazares J, Bhatia N, et al. Once⁃daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double⁃blind, vehicle⁃controlled phase Ⅱb study［J］. Br J Dermatol, 2023,189（4）:392⁃399. doi: 10.1093/bjd/ljad182. |
| ［38］ | Zhu Y, Zhou Y, Ma X, et al. Topical therapy in psoriasis: clinical benefits, advances in novel drug delivery strategies, and gene therapy regimen［J］. Pharmaceutics, 2025,17（3）:283. doi: 10. 3390/pharmaceutics17030283. |
| ［39］ | Lin CY, Lin ZC, Chang YT, et al. Novel strategies in topical delivery for psoriasis treatment: nanocarriers and energy⁃driven approaches［J］. Expert Opin Drug Deliv, 2025,22（4）:565⁃581. doi: 10.1080/17425247.2025.2472968. |
| ［40］ | Zhang Y, Zang C, Mao M, et al. Advances in RNA therapy for the treatment of autoimmune diseases［J］. Autoimmun Rev, 2025,24（4）:103753. doi: 10.1016/j.autrev.2025.103753. |
| ［41］ | Lwin SM, Snowden JA, Griffiths C. The promise and challenges of cell therapy for psoriasis［J］. Br J Dermatol, 2021,185（5）:887⁃898. doi: 10.1111/bjd.20517. |
| ［42］ | Cheng L, Wang S, Peng C, et al. Human umbilical cord mesenchymal stem cells for psoriasis: a phase 1/2a, single⁃arm study［J］. Signal Transduct Target Ther, 2022,7（1）:263. doi: 10.1038/s41392⁃022⁃01059⁃y. |
| ［43］ | Qiao Z, Zhao W, Liu Y, et al. Low⁃dose interleukin⁃2 for psoriasis therapy based on the regulation of Th17/Treg cell balance in peripheral blood［J］. Inflammation, 2023,46（6）:2359⁃2373. doi: 10.1007/s10753⁃023⁃01883⁃6. |
| ［44］ | Dand N, Stuart PE, Bowes J, et al. GWAS meta⁃analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets［J］. Nat Commun, 2025,16（1）:2051. doi: 10.1038/s41467⁃025⁃56719⁃8. |
| ［45］ | Nussbaum L, Chen YL, Ogg GS. Role of regulatory T cells in psoriasis pathogenesis and treatment［J］. Br J Dermatol, 2021,184（1）:14⁃24. doi: 10.1111/bjd.19380. |
| ［46］ | Eyerich K, Krueger J, Stahle M, et al. An international Delphi consensus to define a clinically appropriate definition of disease modification for plaque psoriasis［J］. J Eur Acad Dermatol Venereol, 2024,38（5）:e424⁃e427. doi: 10.1111/jdv.19652. |
| ［47］ | Lwin SM, Azrielant S, He J, et al. Curing psoriasis［J］. J Invest Dermatol, 2024,144（12）:2645⁃2649. doi: 10.1016/j.jid.2024. 09.012. |
| [1] | 薛珂 陈佳 李斌. 系统性红斑狼疮靶向治疗研究进展[J]. 中华皮肤科杂志, 2025, 58(8): 781-784. |
| [2] | 魏然 李钦峰. 儿童斑秃新型靶向药物治疗研究进展[J]. 中华皮肤科杂志, 2025, 58(7): 650-653. |
| [3] | 李翔倩 张建中 周城. 系统小分子药物和生物制剂治疗斑秃的临床研究进展[J]. 中华皮肤科杂志, 2025, 58(7): 646-649. |
| [4] | 白璐 楚妍 刘园园 朱才勇. 慢性手部湿疹的治疗进展[J]. 中华皮肤科杂志, 2025, 58(5): 477-480. |
| [5] | 中华医学会皮肤性病学分会银屑病学组. [开放获取] 阿普米司特治疗银屑病专家指导意见（2025版）[J]. 中华皮肤科杂志, 2025, 58(5): 416-424. |
| [6] | 中国医师协会皮肤科医师分会 中华医学会皮肤病学分会治疗学组 中国医疗保健国际交流促进会皮肤医学分会 国家皮肤与免疫疾病临床医学研究中心 中国罕见病联盟皮肤罕见病专业委员会. 大疱性类天疱疮诊疗专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(5): 405-415. |
| [7] | 李紫钰 鲁严. 关注新型冠状病毒感染后重症皮肤病[J]. 中华皮肤科杂志, 2025, 58(4): 378-383. |
| [8] | 许秋云 纪超. 坏疽性脓皮病系统合并症的研究进展[J]. 中华皮肤科杂志, 2025, 58(4): 369-373. |
| [9] | 中国医师协会皮肤科医师分会儿童学组 中华医学会皮肤性病学分会银屑病学组. 【开放获取】 儿童脓疱型银屑病诊疗中国专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(4): 297-306. |
| [10] | 何春霞 晋红中. 【开放获取】 急危重皮肤病的诊疗原则、现状、挑战和展望[J]. 中华皮肤科杂志, 2025, 58(4): 307-314. |
| [11] | 木葵 郭慧 文海泉 龙海 刘昱 罗帅寒天 黄馨 周星雨 肖嵘 李亚萍. 基于标准治疗联合泰它西普治疗25例系统性红斑狼疮的疗效和安全性分析[J]. 中华皮肤科杂志, 2025, 58(4): 322-327. |
| [12] | 李秀珍 徐秀莲. 白细胞介素23抑制剂治疗对银屑病共病的影响[J]. 中华皮肤科杂志, 2025, 58(3): 268-272. |
| [13] | 陈良宏 孙艳 王敬玉 吴严. 本维莫德在皮肤病中的研究进展[J]. 中华皮肤科杂志, 2025, 58(3): 266-268. |
| [14] | 王彩霞 徐凡 石晶 朱海莲 卢桂玲 王红梅. 奥马珠单抗和度普利尤单抗治疗大疱性类天疱疮的疗效和安全性系统综述[J]. 中华皮肤科杂志, 2025, 0(3): 20220929-e0220929. |
| [15] | 黄淑黛 周栩悦 张家安 陈崑. 特异性促炎症消退介质在银屑病中的研究进展[J]. 中华皮肤科杂志, 2025, 0(3): 20240503-e0240503. |
|
||
